(21sirtuininhibitor7) 57 (68.7) 26 (31.3) 25 (30.1) 58 (69.9) 35 (42.2) 48 (57.eight) 8 (9.6)

(21sirtuininhibitor7) 57 (68.7) 26 (31.3) 25 (30.1) 58 (69.9) 35 (42.2) 48 (57.eight) 8 (9.6) 53 (63.9) 22 (26.five) 37 (44.6) 46 (55.four)Values are presented as median (range) or variety of sufferers
(21sirtuininhibitor7) 57 (68.7) 26 (31.three) 25 (30.1) 58 (69.9) 35 (42.two) 48 (57.eight) eight (9.six) 53 (63.9) 22 (26.5) 37 (44.six) 46 (55.4)Values are presented as median (range) or number of individuals ( ). WHO, Planet Overall health Organization.www.e-roj.orgCCRT with IMRT in stage III-IV nasopharyngeal carcinomaTable 3. Predictors of disease outcomes in univariate analysis LC Variable All round Age (yr) sirtuininhibitor50 50 Sex Male Female Histology WHO I Ia WHO IIb T classification T1 2 T3 4 N classification N0 N1-2 N3b Stage group III IVA VB NCT (-) (+) NCT or ACT (-) (+) 5-yr rate ( ) 94.7 95.7 94.0 97.9 87.four 100 92.7 90.6 97.9 one hundred 98.1 85.0 97.2 92.6 one hundred 90.five one hundred 92.4 p-valuea) RC 5-yr price ( ) 89.three 92.9 84.eight 90.1 87.8 90.9 88.six 84.0 93.two one hundred 94.0 72.two 94.five 84.9 92.1 86.six 88.8 89.7 p-value DMFS 5-yr price ( ) 77.8 80.4 74.2 72.two 91.6 82.3 76.0 75.0 79.9 87.five 85.7 55.8 93.7 66.0 81.4 75.7 89.4 73.1 p-value DFS 5-yr rate ( ) 64.1 69.9 65.7 68.four 67.2 74.5 65.4 63.two 71.eight 87.five 78.six 36.two 85.eight 54.5 76.8 61.three 82.five 62.1 p-value 5-yr rate ( ) 81.8 88.two 73.6 86.5 72.six 80.0 83.0 84.six 79.five one hundred 83.7 72.0 82.3 81.five 85.four 80.five 82.9 82.two OS p-value0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.sirtuininhibitor0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.LC, regional manage; RC, regional handle; DMFS, distant metastasis-free survival; DFS, disease-free survival; OS, overall survival; WHO, Globe Overall health Organization; NCT, IL-1 beta Protein Source neoadjuvant chemotherapy; ACT, adjuvant chemotherapy. a) Log-rank test.Table four. Treatment-related toxicity profiles in the course of each treatment course Toxicities Hematologic SOD2/Mn-SOD Protein manufacturer Anemia Neutropenia Thrombocytopenia Non-hematologic Mucositis Dermatitis Nausea Weight reduction Infection NCT (n = 41) Grade 3 12 (29.2) 0 (0) 7 (17.1) 0 (0) 1 (2.four) 1 (2.four) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 42 (50.six) five (6.0) 4 (4.8) 1 (1.two) 0 (0) 0 (0) five (12.two) 0 (0) 3 (3.6) 7 (eight.4) 3 (3.six) 48 (57.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Grade 4 CCRT (n = 83) Grade 3 12 (14.five) 0 (0) 1 (1.2) 1 (1.two) 0 (0) five (41.7) 0 1 (8.three) 0 (0) 0 (0) 0 (0) 0 (0) 1 (8.three) Grade 4 ACT (n= 12) Grade three 7 (58.3) 0 (0) 2 (16.7) 0 (0) GradeValues are presented as number ( ). NCT, neoadjuvant chemotherapy; CCRT, concurrent chemoradiation; ACT, adjuvant chemotherapy.dx.doi.org/10.3857/roj.2015.33.two.www.e-roj.orgChan Woo Wee, et al danger of extreme hematologic toxicity at some point for the duration of the therapy course in comparison with sufferers treated by CCRT alone (30.1 vs. 6.0 , respectively; p = 0.005). The use of NCT also showed a non-significant trend towards enhanced serious hematologic toxicity for the duration of CCRT (10.8 vs. three.six , respectively; p = 0.055). Nonetheless, extreme non-hematologic toxicity through CCRT occurred extra generally in individuals treated with no NCT in comparison with these treated with NCT (34.9 vs. 22.9 , respectively; p = 0.035). Inside a comparison of patients treated with CCRT alone and CCRT plus ACT, ACT increased the general threat of severe hematologic toxicity at some point in the course of the therapy course (16.7 vs. 11.9 , respectively; p = 0.007). Severity of xerostomia was recorded within the healthcare records as outlined by the RTOG scale. Severe xerostomia did not take place in the course of RT or follow-up. The rate of clinically assessed xerostomia of any grade was 79.five (66/83), 85.5 (65/76), and 76.9 (50/65) around the final week of RT, a single year post-RT, and two years post-RT, respectively. Nonetheless, the price of grade 2 xerostomia decreased over time and was only 32.five (27/83), 14.five (11/76), and 6.two (4/65) around the final we.